Table 1.
Patients, disease, and transplant characteristics.
| Characteristics | n = 157 |
|---|---|
| RECIPIENTS | |
| Median age, years | 28.4 |
| Male (%) | 91 (58%) |
| Children, 15 year or younger (%) | 39 (25%) |
| Positive CMV serology (%) | 94 (60%) |
| HLA-G | |
| 14 Heterozygote | 76 (48%) |
| 14− Homozygote | 49 (31%) |
| 14+ Homozygote | 32 (21%) |
| Underlying diagnosis | |
| Chronic leukemia (%) | 31 (20%) |
| Acute leukemia (%) | 80 (51%) |
| Other malignant disorders (%) | 25 (16%) |
| Non-malignant disorder | 21 (13%) |
| Disease status for malignant disorders | |
| Early (%) | 107 (79%) |
| Intermediate (%) | 13 (10%) |
| Advanced (%) | 15 (11%) |
| DONORS | |
| Median age | 29.9 |
| Male (%) | 83 (53%) |
| Female donor to male recipient (%) | 43 (27%) |
| ABO major incompatibility (%) | 24 (15%) |
| Positive CMV serology (%) | 80 (51%) |
| HLA-G | |
| 14 Heterozygote | 76 (48%) |
| 14− Homozygote | 49 (31%) |
| 14+ Homozygote | 32 (21%) |
| TRANSPLANTATION | |
| GVHD prophylaxis | |
| CYA A | 5 (3%) |
| CYA A + MTX | 144 (92%) |
| CYA A + others | 3 (2%) |
| Conditioning | |
| TBI-based | 60 (38%) |
| Bu-based | 97 (62%) |
CMV, cytomegalovirus; CYA A, cyclosporin A; MTX, methotrexate; TBI, total body irradiation; Bu, Busulfan.